Diogo Bastos
Overview
Explore the profile of Diogo Bastos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
105
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cirne F, Sedelaar M, Narayan V, Macedo A, Koo C, de Jesus J, et al.
Cardiooncology
. 2025 Mar;
11(1):28.
PMID: 40089789
Advances in the diagnosis and management of prostate cancer have significantly changed the disease landscape. While benefiting from better oncological outcomes, patients are now experiencing higher rates of non-cancer comorbidities,...
2.
Orme J, Taza F, De Sarkar N, Tewari A, Arsalan Naqvi S, Riaz I, et al.
Eur Urol Oncol
. 2023 Dec;
7(4):877-887.
PMID: 38072760
Background And Objective: BRCA2 mutations in metastatic castration-resistant prostate cancer (mCRPC) confer sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors. However, additional factors predicting PARP inhibitor efficacy in mCRPC are needed....
3.
Nabavi N, Mahdavi S, Afshar Ardalan M, Chamanara M, Mosaed R, Lara A, et al.
Biomedicines
. 2023 Jul;
11(7).
PMID: 37509723
Androgen deprivation therapy (ADT) remains the cornerstone of advanced prostate cancer treatment. However, the progression towards castration-resistant prostate cancer is inevitable, as the cancer cells reactivate androgen receptor signaling and...
4.
Taza F, Holler A, Fu W, Wang H, Adra N, Albany C, et al.
JCO Precis Oncol
. 2021 Nov;
5.
PMID: 34778690
Methods: We conducted a multicenter retrospective analysis involving 12 sites. We collected genomic and clinical data from 123 patients with /-altered mCRPC who were treated with PARP inhibitors. The primary...
5.
van der Vossen E, Bastos D, Stols-Goncalves D, de Goffau M, Davids M, Pereira J, et al.
Gut Microbes
. 2021 Nov;
13(1):1993513.
PMID: 34747338
Accumulating evidence shows that microbes with their theater of activity residing within the human intestinal tract (i.e., the gut microbiome) influence host metabolism. Some of the strongest results come from...
6.
Sasse A, Dos Reis R, Nogueira L, Maluf F, Herchenhorn D, Smaletz O, et al.
Int Braz J Urol
. 2019 May;
45(3):449-458.
PMID: 31038861
Prostate cancer is the second most common cancer and the fi fth leading cause of cancer deaths. In Brazil, it is likewise the second most common cancer among men, second...
7.
Mattiolli A, Santos A, Vicente A, Queiroz M, Bastos D, Herchenhorn D, et al.
Int Braz J Urol
. 2018 Aug;
44(5):892-899.
PMID: 30088720
Purpose: The purpose of our study was to evaluate the clinical impact of 68Ga-PSMA PET / CT in the setting of biochemical recurrence of prostate cancer. Materials And Methods: We...
8.
Danila D, Samoila A, Patel C, Schreiber N, Herkal A, Anand A, et al.
Cancer J
. 2016 Oct;
22(5):315-320.
PMID: 27749322
Circulating tumor cell (CTC) number measured with the CellSearch assay is prognostic for survival in metastatic castration-resistant prostate cancer before and after therapy. Using a standard operating protocol for sample...
9.
Queiroz M, Viana P, Santos A, Bastos D, Etchebehere E, Cerri G
Clin Nucl Med
. 2016 Jun;
41(9):e417-9.
PMID: 27276202
A 64-year-old man with history of prostate adenocarcinoma underwent radical prostatectomy in 2003. He remained with undetectable prostate-specific antigen (PSA) levels until 2014, when he then presented rising serum PSA...